MiR-15a/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma
MiR-15a/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma
复制标题
MiR-15a/16通过抑制多发性骨髓瘤中Bcl-2、VEGF-A和IL-17的表达来调节骨髓瘤细胞的生长、血管生成和抗肿瘤免疫
DOI：
10.1016/j.leukres.2016.08.013
复制
发表时间：
2016-10-01
影响因子：
2.7
通讯作者：
Li, Zhenyu
中科院分区：
文献类型：
--
作者：
Li, Yanjie;Zhang, Bingyun;Li, Zhenyu
已经报道miRNA参与许多癌症的发病机制。本文探讨了miR-15 a/16在多发性骨髓瘤（MM）发病中的作用及其机制。我们发现miR-15 a/16在初诊MM患者的骨髓来源的单个核细胞（BM-MNCs）中下调，并且miR-15 a/16的下调与国际分期系统（ISS）分期相关。结果表明，miR-15 a/16可抑制骨髓瘤细胞增殖，并通过抑制抗凋亡蛋白Bcl-2的表达，提高U266细胞的凋亡率。我们还发现miR-15 a/16可以降低骨髓瘤细胞培养上清中VEGF-A和IL-17的水平。这些结果表明，miR-15 a/16可能通过多种调节机制在MM中发挥肿瘤抑制剂的作用，它们可能是MM治疗的潜在靶点。（C）2016 Elsevier Ltd.保留所有权利。
miRNAs have been reported to be involved in the pathogenesis of many cancers. In this article, we investigated the role and the mechanisms of miR-15a/16 in the pathogenesis of multiple myeloma (MM). We found that miR-15a/16 was down-regulated in bone marrow-derived mononuclear cells (BM-MNCs) of newly diagnosed patients with MM and the downregulation of miR-15a/16 was correlated with International Staging System (ISS) stage. We then demonstrated miR-15a/16 inhibited myeloma cells proliferation, and increased apoptosis rate of U266 cells by suppressing the expression of anti-apoptosis protein Bcl-2. We also found miR-15a/16 could decrease VEGF-A and IL-17 levels in the supernatant of myeloma cells. These results indicate that miR-15a/16 may function as a tumor suppressor in MM through multiple regulatory mechanisms and they may be potential targets for the therapy of MM. (C) 2016 Elsevier Ltd. All rights reserved.